バイオシミラー・バイオ後続品の世界市場2020-2030

【英語タイトル】Global Biosimilars and Follow-On Biologics Market 2020-2030

visiongainが出版した調査資料(VGA20DE068)・商品コード:VGA20DE068
・発行会社(調査会社):visiongain
・発行日:2020年4月
・ページ数:420
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:バイオ
◆販売価格オプション(消費税別)
Sigle User(1名様閲覧用)USD5,069 ⇒換算¥547,452見積依頼/購入/質問フォーム
Global Site License(法人閲覧用)USD9,099 ⇒換算¥982,692見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

The global biosimilars and follow-on biologics market is estimated to have reached $19.87bn in 2019 and expected to grow at a CAGR of 7.1% in the first half of the forecast period. The market is dominated by Biosimilar Monoclonal Antibodies, this submarket is estimated to hold 36.5% share of this market in 2020.
How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 420-page report you will receive 131 tables and 90 figures– all unavailable elsewhere.

The 420-page report provides clear detailed insight into the global biosimilars and follow-on biologics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope
• Global Biosimilars and Follow-on Biologics Market forecasts from 2020-2030
• Along with revenue prediction for the overall world market for biosimilars, our investigation shows forecasts to 2029 for 8 individual therapeutic submarkets:
• Monoclonal antibodies (mAbs)
• Fusion proteins
• Insulin
• Erythropoietin (EPO)
• Granulocyte colony-stimulating factor (G-CSF)
• Interferons
• Growth hormones
• Fertility hormones
• This report also shows revenue to 2030 for 11 individual submarkets within the above segments:
• Rituximab, infliximab, trastuzumab, adalimumab and bevacizumab
• Human insulin, insulin analogues, insulin glargine and insulin lispro
• Interferon alfa and interferon beta
• Our analyses show individual revenue forecasts to 2030 for 17 national markets:
• US
• Canada
• Japan
• Germany
• France
• UK
• Italy
• Spain
• Sweden
• Norway
• China
• India
• South Korea
• Russia
• Brazil
• South Africa
• Australia
• Our study discusses the leading companies that are involved in the biosimilars and follow-on biologics industry:
• Amgen Inc
• Biocon Limited
• Celltrion Healthcare Co. Ltd
• Dong-A Socio Holdings Co. Ltd
• Dr.Reddy’s Labs (DRL)
• & Other Companies
• Our study provides a SWOT analysis of the biosimilars and follow-on biologics market.
• Our study discusses pressures, opportunities and other events affecting the biosimilars industry and market, including these influences:
• Strategies for developing biosimilars – needs, demand, challenges and opportunities
• Guidelines from regulators (FDA, EMA and others)
• Patent challenges and data exclusivity for biopharmaceuticals
• Needs and opportunities in developing biosimilar mAbs, including rising incidence of cancers and increasing demand for lower-cost biologicals
• Developments in technology and operations for biosimilar drug production.
Visiongain’s study is intended for anyone requiring commercial analyses for the biosimilars and follow-on biologics market. You find data, trends and predictions.Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.

【レポートの目次】

1 Report Overview
1.1 Biosimilar Overview
1.1.1 Global Biosimilars Market Forecast, 2020-2030
1.2 Biosimilars Market Segmentation
1.3 Why You Should Read this Report
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain
2 An Introduction to Biosimilars and Biosimilar Drug Development
2.1 What are Biologics?
2.1.1 Biologics Can Be Very Effective but Also Very Expensive
2.1.2 Brief History of Biological Drug Development
2.1.3 Why are Biologics the Most Lucrative Products in The Global Pharmaceutical Market?
2.2 What are Biosimilars?
2.3 Brief History of Biosimilars
2.4 What are Interchangeable Biological Products and how do They Differ from Biosimilars?
2.4.1 FDA Guidelines on Prescription of Interchangeables Vs Biosimilars
2.4.2 Where Does the EMA Stand with Regard to Interchangeables?
2.4.3 Where do the EU5 and other European Countries Stand with Regard to Automatic Substitution?
2.4.4 Why Would Nations Oppose Automatic Substitution of Reference Biologics with Biosimilars?
2.5 Main Segments of the Overall Biosimilars Market
2.6 Definitions
2.6.1 EMA Terminology Related to Biosimilars
2.6.2 FDA Terminology Related to Biosimilars
2.6.3 WHO Terminology Related to Biosimilars
2.6.4 Differences Between Common Drug Classifications
3 Market and Technology Background
3.1 Lifecycle of a Biosimilar Drug
3.2 Development of a Biosimilar
3.2.1 Cell Line Development and Selection
3.2.2 E. coli Cells
3.3 Mammalian Cells
3.4 Manufacturing of a Biosimilar
3.5 Preclinical Studies and Validation of a Biosimilar
3.6 Clinical Trials
3.7 Approval by Regulatory Agencies
3.8 Pharmacovigilance/Post-Approval Monitoring
4 Global Biosimilar Market by Type
4.1 Global Biosimilars Market Forecast by Submarket, 202 b0-2030
4.2 Recombinant Hormones
4.2.1 Human Growth Hormone: First Extracted in 1958
4.2.2 Biosimilar Growth Hormones Market Forecast, 2020-2030
4.3 Fertility Hormones
4.3.1 Two Products Lead the Branded Fertility Hormone Market
4.3.2 Long-Acting Follicle Stimulating Hormone (FSH)
4.3.3 Branded Fertility Hormones Market Outlook
4.3.4 Rising Infertility to Drive Demand to 2030
4.3.5 Biosimilar Fertility Hormones Market Forecast, 2020-2030
4.3.6 Human Growth Hormone (HGH)
4.3.7 Follicle-Stimulating Hormone (FSH)
4.4 Recombinant Growth Factors
4.4.1 Erythropoietin (EPO)
4.4.2 Biosimilar EPO Market Forecast, 2020-2030
4.4.3 Granulocyte-Colony Stimulating Factor (G-CSF)
4.4.4 Biosimilar EPO Market Forecast, 2020-2030
4.5 Insulin
4.5.1 Global Biosimilar Insulin Revenue Forecast, 2020-2030
4.5.2 Global Biosimilar Insulin Market Share, 2020-2030
4.5.3 Biosimilar Human Insulin Submarket Forecast, 2020-2030
4.5.4 Biosimilar Insulin Analogues Submarket, 2020-2030
4.5.5 Biosimilar Insulin Analogue Revenue Forecast, 2020-2030
4.6 Biosimilar Insulin Glargine
4.6.1 Biosimilar Insulin Glargine: Revenue Forecast, 2020-2030
4.7 Biosimilar Insulin Lispro
4.7.1 Biosimilar Insulin Lispro: Revenue Forecast, 2020-2030
4.8 Monoclonal Antibodies (mAbs)
4.8.1 Biosimilar Monoclonal Antibodies Market and Submarkets Forecast, 2020-2030
4.8.2 Global Biosimilar Monoclonal Antibodies Market Share, 2020-2030
4.8.3 Biosimilar Rituximab
4.8.4 Biosimilar Infliximab
4.8.5 Biosimilar Trastuzumab
4.8.6 Biosimilar Adalimumab
4.8.7 Biosimilar Bevacizumab
4.9 Fusion Proteins
4.10 Interferons
4.10.1 Biosimilar Interferon Market Forecast, 2020-2030
4.10.2 Global Biosimilar Interferons Market Share, 2020-2030
4.11 Biosimilar Interferon Alfa
4.11.1 Biosimilar Interferon Alfa – a Common Target in Developing Countries, leading to Fragmented Markets
4.11.2 Biosimilar Peginterferon Alfa
4.11.3 Biosimilar Interferon Alfa Submarket Forecast, 2020-2030
4.12 Biosimilar Interferon Beta
4.12.1 Biosimilars are Well-Established in Emerging Markets
4.12.2 Biosimilar Interferon Beta Pipeline
4.12.3 Long-Acting Interferon Beta
4.12.4 Biosimilar Interferon Beta Submarket Forecast, 2020-2030
4.13 Strategies to Develop Biobetters
4.13.1 PEGylation
4.13.2 Glycosylation
4.13.3 Fusion Proteins
4.14 Others
4.14.1 Low Molecular Weight Heparins
4.15 FDA Guidance to LMWH Biosimilars
4.15.1 EMA Guidance to LMWH Biosimilars
5 Biosimilars: Qualitative Analysis and Industry Trends
5.1 Analysis of Market Opportunities
5.2 Strengths of Biosimilars Market
5.2.1 Growing Aging Population
5.2.2 Rising Incidence of Diseases
5.2.3 Patent Expirations
5.2.4 Growing Pipeline
5.2.5 Drive to Reduce Costs
5.2.6 Government Incentives
5.2.7 Incentives in Europe
5.2.8 Incentives in Indian Market
5.2.9 Collaborations and Partnerships
5.2.10 Mergers and Acquisitions
5.3 Weaknesses of Biosimilars Market
5.3.1 Manufacturing Process of Biosimilars
5.3.2 Process Definition and Testing and Validation
5.3.3 Lack of Skilled Personnel
5.3.4 Regulatory Guidelines
5.3.5 Interchangeability
5.3.6 Nomenclature of Biosimilars
5.3.7 Patent Litigation
5.4 Threats in Biosimilars Market
5.4.1 Unpredictable Regulatory Landscape
5.4.2 Prescription by Medical Practitioners/Pharmacies
5.4.3 Competition
5.5 Opportunities in Biosimilars Market
5.5.1 Emerging Markets
5.5.2 Technological Innovation and Improved Process Knowledge
5.5.3 Pricing
5.6 Biosimilars Product Pipeline
6 Global Biosimilars and Follow-on Biologics Market Breakdown by Application
6.1 Market by Biosimilar Applications
6.1.1 Global Biosimilar Market by Application: Revenue Forecast, 2020-2030
6.1.2 Global Biosimilar Application Market Share, 2020-2030
6.2 Cancer Biosimilars
6.2.1 Market Overview
6.3 Blood Disorders
6.3.1 Market Overview
6.3.2 Market Revenue
6.4 Diabetes
6.4.1 Market Overview
6.4.2 Market Revenue
6.5 Growth Hormone Deficiency
6.5.1 Market Overview
6.5.2 Market Revenue
6.6 Infectious Diseases
6.6.1 Market Overview
6.6.2 Market Revenue
6.7 Autoimmune Diseases
6.7.1 Market Overview
6.7.2 Market Revenue
6.8 Other Diseases
6.8.1 Market Overview
6.8.2 Market Revenue
7 Global Biosimilars Market Outlook by Country, 2020-2030
7.1 National Submarket Forecasts 2020-2030
7.1.1 Global Biosimilar Market by Nation: Revenue Forecast, 2020-2030
7.2 Regional Market Overview
7.2.1 Global Biosimilar Market Share by Nation, 2020-2030
7.3 US Biosimilars Market Outlook 2020-2030
7.3.1 FDA Finalises Three New Guidelines on 351(k) Applications in April 2015
7.3.2 FDA Finally Releases Guidance on Biosimilar Naming
7.3.3 Individual States Can Pass their Own Biosimilar Substitution Laws
7.3.4 US Biosimilars Market Forecast 2020-2030
7.4 Canada Biosimilar Market Outlook, 2020
7.4.1 Canada Biosimilar Market Forecast, 2020-2030
7.5 The EU Biosimilar Market: History and Current Status
7.5.1 History of EMA Guidelines and Updates
7.5.2 Biosimilar Uptake in Europe Varies between Nations
7.5.3 European Biosimilars Market Forecast, 2020-2030
7.5.4 Inflectra and Remsima in Europe – Demonstrates a Path for Other Biosimilar mAbs
7.6 German Biosimilar Market Outlook, 2020
7.6.1 German Biosimilar Market Forecast, 2020-2030
7.7 French Biosimilars Market Outlook, 2020
7.7.1 Biosimilar Substitution Passed but Requires Decrees to Come into Effect, Expected Sometime This Year
7.7.2 French Biosimilar Market Forecast, 2020-2030
7.8 UK Biosimilar Market Outlook, 2020
7.8.1 UK Biosimilar Market Forecast, 2020-2030
7.9 Italian Biosimilars Market Outlook, 2020
7.9.1 Italian Biosimilars Market Forecast, 2020-2030
7.10 Spanish Biosimilars Market Outlook, 2020
7.10.1 Spanish Biosimilar Market Forecast, 2020-2030
7.11 Sweden Biosimilars Market Outlook, 2020
7.11.1 Sweden Biosimilar Market Forecast, 2020-2030
7.12 Norway Biosimilars Market Outlook, 2020
7.12.1 Norway Biosimilar Market Forecast, 2020-2030
7.13 Japan Biosimilars Market Outlook, 2020
7.13.1 Biosimilar Regulation in Japan and Currently Approved Biosimilars
7.13.2 Differences between the European and Japanese Guidelines
7.13.3 Currently Approved Biosimilars in Japan
7.13.4 Japanese Biosimilar Market Forecast, 2020-2030
8 Outlook for Biosimilars in Emerging Markets, 2020-2030
8.1 China and India Lead Biosimilar Revenues
8.2 Leading Emerging Biosimilar Markets Forecast, 2020-2030
8.3 Chinese Biosimilars Market Outlook, 2020
8.3.1 China Publishes Final Guidelines for Biosimilars
8.3.2 Chinese Biosimilars Market Forecast, 2020-2030
8.4 Indian Biosimilars Market Outlook, 2020
8.4.1 CDSCO Guidelines Released in 2012
8.4.2 Indian Biosimilars Market Forecast, 2020-2030
8.5 South Korea’s Established Biosimilar Guidelines
8.5.1 Currently Approved Biosimilars in South Korea, 2019
8.6 Russian Biosimilars Market Outlook and Forecast, 2020-2030
8.7 Brazilian Biosimilars Market Outlook and Forecast, 2020-2030
8.7.1 Brazilian Biosimilar Regulation
8.7.2 Government Eager to Promote Biosimilar Development, And Two Major Conglomerates, Bionovis And Orygen, Are Racing to Produce Biosimilars
8.7.3 Brazilian Biosimilars Market Forecast, 2020-2030
8.8 South Africa Biosimilars Market Outlook, 2020
8.8.1 South Africa Biosimilar Market Forecast, 2020-2030
8.9 Australia Biosimilars Market Outlook, 2020
8.9.1 Australia Biosimilar Market Forecast, 2020-2030
9 Industry Structure
9.1 Types of Market Players
9.1.1 Established Biologics Companies
9.1.2 Established Generics Companies
9.1.3 Bio-intellectual Companies
9.1.4 Opportunistic Companies
9.2 Emerging Trends in Biosimilar Industry Structure
9.2.1 Collaborations and Partnerships
9.2.2 Mergers and Acquisitions
9.2.3 Contract Manufacturing Organizations (CMOs)
9.3 Losses of Exclusivity- A Determining Factor
9.4 Biosimilar Market Entry Dates
9.5 Biosimilars in the Pipeline
9.5.1 Humira (adalimumab)
9.5.2 Enbrel (etanercept)
9.5.3 Lucentis (ranibizumab)
9.5.4 Actemra IV (tocilizumab)
9.5.5 Eylea (aflibercept)
9.6 Outsourcing Biosimilar Development
9.6.1 A Biosimilar Company Perspective
9.6.2 Business Model Differences
10 Leading Manufacturers/Suppliers of Biosimilar Drugs
10.1 Market Share
10.2 Recombinant Growth Factors
10.2.1 Market Share
10.3 Monoclonal Antibodies
10.3.1 Market Share
10.4 Fusion Proteins
10.4.1 Market Share
10.5 Others
10.5.1 Market Share
11 Company Profiles
11.1 Amgen Inc.
11.1.1 Company Overview
11.1.2 Company Financials
11.1.3 Company Recent Developments
11.2 Biocon Limited
11.2.1 Company Overview
11.2.2 Company Financials
11.2.3 Company Recent Developments
11.3 Celltrion Healthcare Co. Ltd.
11.3.1 Company Overview
11.3.2 Company Financials
11.3.3 Company Recent Developments
11.4 Dong-A Socio Holdings
11.4.1 Company Overview
11.4.2 Company Financials
11.4.3 Company Recent Developments
11.5 Dr. Reddy’s Laboratories Ltd.
11.5.1 Company Overview
11.5.2 Company Financials
11.5.3 Company Recent Developments
11.6 F Hoffmann-La Roche Ltd.
11.6.1 Company Overview
11.6.2 Company Financials
11.6.3 Company Recent Developments
11.7 Pfizer Inc.
11.7.1 Company Overview
11.7.2 Company Financials
11.7.3 Company Recent Developments
11.8 Stada Arzneimittel AG
11.8.1 Company Overview
11.8.2 Company Financials
11.8.3 Company Recent Developments
11.9 Teva Pharmaceutical Industries Ltd.
11.9.1 Company Overview
11.9.2 Company Financials
11.9.3 Company Recent Developments
11.10 Wockhardt Limited
11.10.1 Company Overview
11.10.2 Company Financials
11.10.3 Company Recent Developments
11.11 3S BIO INC.
11.11.1 Company Overview
11.11.2 Company Financials
11.12 CELLTRION INC.
11.12.1 Company Overview
11.12.2 Company Financials
11.13 GENEXINE INC.
11.13.1 Company Overview
11.14 MYLAN N.V.
11.14.1 Company Overview
11.14.2 Company Financials
11.15 ZYDUS CADILA
11.15.1 Company Overview
11.15.2 Company Financials
11.16 NIPPON KAYAKU CO. LTD.
11.16.1 Company Overview
11.16.2 Company Financials
11.17 MABXIENCE S.A.
11.17.1 Company Overview
11.18 LG LIFE SCIENCES
11.18.1 Company Overview
11.19 Intas Pharmaceuticals Ltd.
11.19.1 Company Overview
11.20 Gedeon Richter Plc
11.20.1 Company Overview
12 Global Biosimilar Patent Review
12.1 Patent Regulations in Favour of Branded Biologics
12.2 Market Exclusivity
12.2.1 Patent Dance
12.2.2 Licensing Notice
12.3 Patent Regulations in Favour of Biosimilars-Emerging Trends
12.3.1 Market Exclusivity Option
12.4 Patent Dance Developments
12.4.1 Licensing Notice
12.4.2 Product vs Process Patents
12.5 Patent Activity in Biosimilars, 2015-2019
12.5.1 United States Patents
12.5.2 Patents by Type
13 New Developments in Global Biosimilars Market
13.1 Major Companies in the Biosimilars Market
13.2 Biosimilars in Clinical Trials
13.3 Overview
13.3.1 Biosimilar Recombinant Hormones in Clinical Trials
13.4 Biosimilar Recombinant Growth Factors in Clinical Trials
13.5 Biosimilar Monoclonal Antibodies in Clinical Trials
13.6 Biosimilar Fusion Proteins in Clinical Trials
13.7 Other Biosimilars in Clinical Trials
13.8 Bio-betters in Clinical Trials
13.9 Significant Regulatory Activities
14 COVID-19 Impact on The Pharmaceutical Supply Chain
14.1 COVID-19 Impact on the Biosimilar Supply Chain
14.2 Health Care Services (HCPS) And Other Health Policy-Makers Unavailable:
14.3 Biosimilars See Some Positive Momentum, Despite Covid-19
14.4 Future Changes to Manufacturing Practices
15 Conclusions from Visiongain’s Research and Analysis
15.1 Rapid Growth Expected for this High-Potential Market
15.2 Biosimilar Monoclonal Antibodies to be the Fastest Growing Segment
15.3 A Range of Factors Will Stimulate Demand
15.4 Challenges Remain in Developing and Successfully Launching Biosimilars
Some Associated Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
List of Tables
Table 1.1 Global Biosimilars Market Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 2.1 First Approvals for Recombinant Protein Therapies, 1982-1993
Table 2.2 Small Molecular Drugs vs. Biologics
Table 2.3 Generics vs. Biosimilars
Table 2.4 Biosimilars vs. Biobetters
Table 3.1 List of Biosimilars Produced in E. Coli
Table 3.2 List of Biosimilars Produced in Mammalian Cells
Table 3.3 Key Differences in Approval Pathways for Biosimilars, European Union (EU) vs. United Sates (U.S.)
Table 3.4 US Approved Biosimilars As of December 2019
Table 4.1 Biosimilars Market Forecast by Product Type: Revenue ($billion), AGR (%), CAGR (%),2020-2030
Table 4.2 Biosimilar Growth Hormone Market Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 4.3 Biosimilar Fertility Hormone Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2030
Table 4.4 Biosimilar Recombinant Hormones
Table 4.5 Biosimilar EPO Market Forecast: Revenue ($billion), AGR (%), CAGR (%),2020-2030
Table 4.6 Biosimilar Recombinant Growth Factors
Table 4.7 Biosimilar G-CSF Market Forecast: Revenue ($billion), AGR (%), CAGR (%),2020-2030
Table 4.8 Biosimilar Insulin Market Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 4.9 Biosimilar Human Insulin Submarkets Forecast: Revenue ($billion), AGR (%), CAGR (%), 2019-2030
Table 4.10 Biosimilar Insulin Analogues Market Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 4.11 Biosimilar Insulin Glargine Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 4.12 Biosimilar Insulin Lispro Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 4.13 Biosimilar Monoclonal Antibodies
Table 4.14 Biosimilar Monoclonal Antibodies Market Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 4.15 Biosimilar Monoclonal Antibodies Market and Submarkets Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 4.16 Biosimilar Rituximab Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 4.17 Biosimilar Infliximab Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 4.18 Biosimilar Trastuzumab Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 4.19 Biosimilar Adalimumab Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 4.20 Biosimilar Bevacizumab Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 4.21 Biosimilar Fusion Proteins
Table 4.22 Fusion Proteins Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 4.23 Biosimilar Interferons Market Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 4.24 Selected Interferon Alfa Biosimilars Approved Worldwide, 2019
Table 4.25 Biosimilar Interferon Alfa Market Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 4.26 Selected Interferon Beta Biosimilars Approved Worldwide
Table 4.27 Biosimilar Interferon Alfa Market Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 4.28 Biosimilar LMWHs
Table 5.1 Biosimilars Product Pipeline
Table 6.1 Global Biosimilar Application Revenue Forecast by Type: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 6.2 Cancer Biosimilar Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 6.3 Blood Disorder Biosimilar Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 6.4 Diabetes Biosimilar Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 6.5 GHD Biosimilar Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 6.6 Infectious Disease Biosimilar Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 6.7 Autoimmune Diseases Biosimilar Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 6.8 Other Diseases Biosimilar Application Revenue Forecast: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 7.1 Biosimilars Market Forecast by Nations: Revenue ($billion), AGR (%), CAGR (%),2020-2030
Table 7.2 US Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%),2020-2030
Table 7.3 Canada Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%),2020-2030
Table 7.4: European Biosimilar Approvals To-Date, 2019
Table 7.5 European Biosimilar Market Segmented by Leading Nations: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 7.6 Germany Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 7.7 France Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%),2020-2030
Table 7.8 UK Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 7.9 Italy Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 7.10 Spain Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%),2020-2030
Table 7.11 Sweden Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%),2020-2030
Table 7.12 Norway Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%),2020-2030
Table 7.13: Japanese Biosimilar Approvals To-Date, 2019
Table 7.14 Japan Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%),2020-2030
Table 8.1 Leading Emerging Biosimilar Markets: Revenue ($billion), AGR (%), CAGR (%), Market Share (%), 2020-2030
Table 8.2 China Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 8.3 India Biosimilars Market: Revenue ($billion), AGR (%), CAGR (%), 2020-2030
Table 8.4: Currently Approved Biosimilars in South Korea, 2019
Table 8.5 South Korea Biosimilars Market: Revenue ($billion), AGR



★調査レポート[バイオシミラー・バイオ後続品の世界市場2020-2030] (コード:VGA20DE068)販売に関する免責事項を必ずご確認ください。
★調査レポート[バイオシミラー・バイオ後続品の世界市場2020-2030]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆